24:00 cardiovascular drugs - alberta blue cross
TRANSCRIPT
24:0
0 C
ard
iovascu
lar D
rug
s
24:00
Cardiovascular Drugs
ALBERTA DRUG BENEFIT LIST
DISOPYRAMIDE
MEXILETINE HCL
FLECAINIDE ACETATE
PROPAFENONE HCL
100 MG ORAL CAPSULE
100 MG ORAL CAPSULE
200 MG ORAL CAPSULE
50 MG ORAL TABLET
100 MG ORAL TABLET
150 MG ORAL TABLET
300 MG ORAL TABLET
00002224801
00002230359
00002230360
0000227553800002459957
0000227554600002459965
000022433240000245717200000603708
000022433250000245716400000603716
RYTHMODAN
NOVO-MEXILETINE
NOVO-MEXILETINE
APO-FLECAINIDEAURO-FLECAINIDE
APO-FLECAINIDEAURO-FLECAINIDE
APO-PROPAFENONEMYLAN-PROPAFENONERYTHMOL
APO-PROPAFENONEMYLAN-PROPAFENONERYTHMOL
SAV
TEV
TEV
APXAUR
APXAUR
APXMYPBGP
APXMYPBGP
(CLASS IA ANTIARRYTHMICS)
(CLASS IB ANTIARRYTHMICS)
(CLASS IC ANTIARRYTHMICS)
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CARDIAC DRUGS
CARDIAC DRUGS
CARDIAC DRUGS
24
24
24
:00
:00
:00
24:04.04.04
24:04.04.08
24:04.04.12
0.2900
1.4915
1.9974
0.2778 0.2778
0.5558 0.5558
0.2965 0.2965 1.2264
0.5227 0.5227 2.1617
39 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$
$
$
$$
$$
$$$
$$$
ANTIARRHYTHMIC AGENTS
ANTIARRHYTHMIC AGENTS
ANTIARRHYTHMIC AGENTS
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
AMIODARONE HCL
DIGOXIN
CHOLESTYRAMINE RESIN
COLESEVELAM HCL
COLESTIPOL HCL
100 MG ORAL TABLET
200 MG ORAL TABLET
0.0625 MG ORAL TABLET
0.125 MG ORAL TABLET
0.25 MG ORAL TABLET
0.05 MG / ML ORAL ELIXIR
4 G ORAL POWDER PACKET
625 MG ORAL TABLET
3.75 G ORAL POWDER PACKET
1 G ORAL TABLET
00002292173
00002364336000023854650000224619400002240604000022424720000224383600002239835
00002335700
00002335719
00002335727
00002242320
000024556090000089096000002210320
00002373955
00002432463
00002132680
PMS-AMIODARONE
AMIODARONEAMIODARONEAPO-AMIODARONEMYLAN-AMIODARONEPMS-AMIODARONESANDOZ AMIODARONETEVA-AMIODARONE
TOLOXIN
TOLOXIN
TOLOXIN
TOLOXIN PEDIATRIC
CHOLESTYRAMINE-ODANOLESTYR LIGHTOLESTYR REGULAR
LODALIS
LODALIS
COLESTID
PMS
SNSSIVAPXMYPPMSSDZTEV
PPH
PPH
PPH
PPH
ODNPMSPMS
VCL
VCL
PFI
(CLASS III ANTIARRYTHMICS)
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CARDIAC DRUGS
CARDIAC DRUGS
ANTILIPEMIC AGENTS
24
24
24
:00
:00
:00
24:04.04.20
24:04.08
24:06.04
0.8466
0.3706 0.3706 0.3706 0.3706 0.3706 0.3706 0.3706
0.3018
0.3018
0.3018
1.2487
0.5275 0.5275 0.5275
1.1456
6.8741
0.2778
40 EFFECTIVE APRIL 1, 2018
$
$$$$$$$
$
$
$
$
$$$
$
$
$
ANTIARRHYTHMIC AGENTS
(CARDIOTONIC AGENTS)
(BILE ACID SEQUESTRANTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
BEZAFIBRATE
FENOFIBRATE
GEMFIBROZIL
400 MG ORAL SUSTAINED-RELEASE TABLET
100 MG ORAL TABLET
67 MG ORAL CAPSULE
100 MG ORAL CAPSULE
200 MG ORAL CAPSULE
160 MG ORAL CAPSULE/TABLET
600 MG ORAL TABLET
300 MG ORAL CAPSULE
0000245331200002083523
0000224685900002288044
00002243180
00002225980
0000223986400002250039
000022468600000228805200002241602
0000197958200002142074
0000197957400002241704
JAMP-BEZAFIBRATEBEZALIP
APO-FENO-SUPERSANDOZ FENOFIBRATE S
APO-FENO-MICRO
APO-FENOFIBRATE
APO-FENO-MICRORATIO-FENOFIBRATE MC
APO-FENO-SUPER (TABLET)SANDOZ FENOFIBRATE S (TABLET)LIPIDIL SUPRA (TABLET)
APO-GEMFIBROZILTEVA-GEMFIBROZIL
APO-GEMFIBROZILTEVA-GEMFIBROZIL
JPCACV
APXSDZ
APX
APX
APXTEV
APXSDZBGP
APXTEV
APXTEV
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
24:00
24:06.06
1.7460 2.1131
0.5406 0.5406
0.5479
0.6105
0.2722 0.2722
0.2723 0.2723 1.3092
0.5157 0.5415
0.1288 0.1352
41 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$
$$
$
$
$$
$$$
$$
$$
(FIBRIC ACID DERIVATIVES)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
ATORVASTATIN CALCIUM10 MG (BASE) ORAL TABLET
20 MG (BASE) ORAL TABLET
40 MG (BASE) ORAL TABLET
0000229526100002348705000024113500000240725600002391058000024540170000239293300002399377000023137070000235029700002417936000023249460000231089900002230711
0000229528800002348713000024113690000240726400002391066000024540250000239294100002399385000023137150000235031900002417944000023249540000231090200002230713
0000229529600002348721000024113770000240727200002391074000024540330000239296800002399393000023137230000235032700002417952000023249620000231091000002230714
APO-ATORVASTATINATORVASTATINATORVASTATIN-10AURO-ATORVASTATINJAMP-ATORVASTATINMAR-ATORVASTATINMYLAN-ATORVASTATINPMS-ATORVASTATINRAN-ATORVASTATINRATIO-ATORVASTATINREDDY-ATORVASTATINSANDOZ ATORVASTATINTEVA-ATORVASTATINLIPITOR
APO-ATORVASTATINATORVASTATINATORVASTATIN-20AURO-ATORVASTATINJAMP-ATORVASTATINMAR-ATORVASTATINMYLAN-ATORVASTATINPMS-ATORVASTATINRAN-ATORVASTATINRATIO-ATORVASTATINREDDY-ATORVASTATINSANDOZ ATORVASTATINTEVA-ATORVASTATINLIPITOR
APO-ATORVASTATINATORVASTATINATORVASTATIN-40AURO-ATORVASTATINJAMP-ATORVASTATINMAR-ATORVASTATINMYLAN-ATORVASTATINPMS-ATORVASTATINRAN-ATORVASTATINRATIO-ATORVASTATINREDDY-ATORVASTATINSANDOZ ATORVASTATINTEVA-ATORVASTATINLIPITOR
APXSNSSIVAURJPCMARMYPPMSRANTEVDRLSDZTEVPFI
APXSNSSIVAURJPCMARMYPPMSRANTEVDRLSDZTEVPFI
APXSNSSIVAURJPCMARMYPPMSRANTEVDRLSDZTEVPFI
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
24:00
24:06.08
0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 0.1743 1.8223
0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 0.2179 2.2779
0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 2.4483
42 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$$$$$
$$$$$$$$$$$$$$
$$$$$$$$$$$$$$
(HMG-COA REDUCTASE INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
ATORVASTATIN CALCIUM
FLUVASTATIN SODIUM
LOVASTATIN
80 MG (BASE) ORAL TABLET
80 MG (BASE) ORAL EXTENDED-RELEASE TABLET
20 MG (BASE) ORAL CAPSULE
40 MG (BASE) ORAL CAPSULE
20 MG ORAL TABLET
40 MG ORAL TABLET
00002295318000023487480000241138500002407280000023910820000245404100002392976000023994070000231375800002417960000023249700000231092900002243097
00002250527
00002299224
00002299232
000022201720000224857200002353229
000022201800000224857300002353237
APO-ATORVASTATINATORVASTATINATORVASTATIN-80AURO-ATORVASTATINJAMP-ATORVASTATINMAR-ATORVASTATINMYLAN-ATORVASTATINPMS-ATORVASTATINRAN-ATORVASTATINREDDY-ATORVASTATINSANDOZ ATORVASTATINTEVA-ATORVASTATINLIPITOR
LESCOL XL
TEVA-FLUVASTATIN
TEVA-FLUVASTATIN
APO-LOVASTATINCO LOVASTATINLOVASTATIN
APO-LOVASTATINCO LOVASTATINLOVASTATIN
APXSNSSIVAURJPCMARMYPPMSRANDRLSDZTEVPFI
NOV
TEV
TEV
APXAPHSNS
APXAPHSNS
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
24:00
24:06.08
0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 0.2342 2.4483
1.5896
0.2312
0.3579
0.4919 0.4919 0.4919
0.8985 0.8985 0.8985
43 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$$$$$
$
$
$
$$$
$$$
(HMG-COA REDUCTASE INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
PRAVASTATIN SODIUM10 MG ORAL TABLET
20 MG ORAL TABLET
40 MG ORAL TABLET
00002248182000022435060000233095400002432048000023174510000224765500002356546000023897030000228442100002247008
0000224818300002243507000023309620000243205600002317478000022476560000235655400002389738000022844480000224700900000893757
0000224818400002243508000023309700000243206400002317486000022476570000235656200002389746000022844560000224701000002222051
ACT PRAVASTATINAPO-PRAVASTATINJAMP-PRAVASTATINMAR-PRAVASTATINMINT-PRAVASTATINPMS-PRAVASTATINPRAVASTATINPRAVASTATINRAN-PRAVASTATINTEVA-PRAVASTATIN
ACT PRAVASTATINAPO-PRAVASTATINJAMP-PRAVASTATINMAR-PRAVASTATINMINT-PRAVASTATINPMS-PRAVASTATINPRAVASTATINPRAVASTATINRAN-PRAVASTATINTEVA-PRAVASTATINPRAVACHOL
ACT PRAVASTATINAPO-PRAVASTATINJAMP-PRAVASTATINMAR-PRAVASTATINMINT-PRAVASTATINPMS-PRAVASTATINPRAVASTATINPRAVASTATINRAN-PRAVASTATINTEVA-PRAVASTATINPRAVACHOL
APHAPXJPCMARMPIPMSSNSSIVRANTEV
APHAPXJPCMARMPIPMSSNSSIVRANTEVBMS
APHAPXJPCMARMPIPMSSNSSIVRANTEVBMS
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
24:00
24:06.08
0.2916 0.2916 0.2916 0.2916 0.2916 0.2916 0.2916 0.2916 0.2916 0.2916
0.3440 0.3440 0.3440 0.3440 0.3440 0.3440 0.3440 0.3440 0.3440 0.3440 1.1243
0.4143 0.4143 0.4143 0.4143 0.4143 0.4143 0.4143 0.4143 0.4143 0.4143 1.3543
44 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$
$$$$$$$$$$$
$$$$$$$$$$$
(HMG-COA REDUCTASE INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
ROSUVASTATIN CALCIUM5 MG (BASE) ORAL TABLET
10 MG (BASE) ORAL TABLET
20 MG (BASE) ORAL TABLET
000023397650000233797500002442574000023912520000241305100002399164000023977810000238126500002378523000023826440000240562800002411628000023387260000235460800002265540
000023397730000233798300002442582000023912600000241307800002399172000023978030000238127300002378531000023826520000240563600002411636000023387340000235461600002247162
000023397810000233799100002442590000023912790000241308600002399180000023978110000238128100002378558000023826600000240564400002411644000023387420000235462400002247163
ACT ROSUVASTATINAPO-ROSUVASTATINAURO-ROSUVASTATINJAMP-ROSUVASTATINMAR-ROSUVASTATINMED-ROSUVASTATINMINT-ROSUVASTATINMYLAN-ROSUVASTATINPMS-ROSUVASTATINRAN-ROSUVASTATINROSUVASTATINROSUVASTATIN-5SANDOZ ROSUVASTATINTEVA-ROSUVASTATINCRESTOR
ACT ROSUVASTATINAPO-ROSUVASTATINAURO-ROSUVASTATINJAMP-ROSUVASTATINMAR-ROSUVASTATINMED-ROSUVASTATINMINT-ROSUVASTATINMYLAN-ROSUVASTATINPMS-ROSUVASTATINRAN-ROSUVASTATINROSUVASTATINROSUVASTATIN-10SANDOZ ROSUVASTATINTEVA-ROSUVASTATINCRESTOR
ACT ROSUVASTATINAPO-ROSUVASTATINAURO-ROSUVASTATINJAMP-ROSUVASTATINMAR-ROSUVASTATINMED-ROSUVASTATINMINT-ROSUVASTATINMYLAN-ROSUVASTATINPMS-ROSUVASTATINRAN-ROSUVASTATINROSUVASTATINROSUVASTATIN-20SANDOZ ROSUVASTATINTEVA-ROSUVASTATINCRESTOR
APHAPXAURJPCMARGMPMPIMYPPMSRANSNSSIVSDZTEVAZC
APHAPXAURJPCMARGMPMPIMYPPMSRANSNSSIVSDZTEVAZC
APHAPXAURJPCMARGMPMPIMYPPMSRANSNSSIVSDZTEVAZC
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
24:00
24:06.08
0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 0.1284 1.3210
0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 0.1354 1.3722
0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 0.1692 1.7152
45 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$$$$$$$
$$$$$$$$$$$$$$$
$$$$$$$$$$$$$$$
(HMG-COA REDUCTASE INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
ROSUVASTATIN CALCIUM
SIMVASTATIN
40 MG (BASE) ORAL TABLET
5 MG ORAL TABLET
10 MG ORAL TABLET
000023398030000233800900002442604000023912870000241310800002399199000023978380000238130300002378566000023826790000240565200002411652000023387500000235463200002247164
0000224701100002405148000023755910000237503600002372932000022465820000226925200002329131000022847230000238629100002250144
000022470120000240515600002375605000023750440000237294000002246583000022692600000232915800002284731000023863050000225015200000884332
ACT ROSUVASTATINAPO-ROSUVASTATINAURO-ROSUVASTATINJAMP-ROSUVASTATINMAR-ROSUVASTATINMED-ROSUVASTATINMINT-ROSUVASTATINMYLAN-ROSUVASTATINPMS-ROSUVASTATINRAN-ROSUVASTATINROSUVASTATINROSUVASTATIN-40SANDOZ ROSUVASTATINTEVA-ROSUVASTATINCRESTOR
APO-SIMVASTATINAURO-SIMVASTATINJAMP-SIMVASTATINMAR-SIMVASTATINMINT-SIMVASTATINMYLAN-SIMVASTATINPMS-SIMVASTATINRAN-SIMVASTATINSIMVASTATINSIMVASTATINTEVA-SIMVASTATIN
APO-SIMVASTATINAURO-SIMVASTATINJAMP-SIMVASTATINMAR-SIMVASTATINMINT-SIMVASTATINMYLAN-SIMVASTATINPMS-SIMVASTATINRAN-SIMVASTATINSIMVASTATINSIMVASTATINTEVA-SIMVASTATINZOCOR
APHAPXAURJPCMARGMPMPIMYPPMSRANSNSSIVSDZTEVAZC
APXAURJPCMARMPIMYPPMSRANSNSSIVTEV
APXAURJPCMARMPIMYPPMSRANSNSSIVTEVMFC
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
24:00
24:06.08
0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 0.1990 2.0076
0.1023 0.1023 0.1023 0.1023 0.1023 0.1023 0.1023 0.1023 0.1023 0.1023 0.1023
0.2023 0.2023 0.2023 0.2023 0.2023 0.2023 0.2023 0.2023 0.2023 0.2023 0.2023 2.2268
46 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$$$$$$
$$$$$$$$$$$
$$$$$$$$$$$$
(HMG-COA REDUCTASE INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
SIMVASTATIN
CLONIDINE HCL
20 MG ORAL TABLET
40 MG ORAL TABLET
80 MG ORAL TABLET
0.1 MG ORAL TABLET
0.2 MG ORAL TABLET
000022470130000240516400002375613000023750520000237295900002246737000022692790000232916600002284758000023863130000225016000000884340
000022470140000240517200002375621000023750600000237296700002246584000022692870000232917400002284766000023863210000225017900000884359
0000224701500002405180000023756480000237507900002372975000022465850000226929500002329182000022847740000238634800002250187
0000246219200002046121
0000246220600002046148
APO-SIMVASTATINAURO-SIMVASTATINJAMP-SIMVASTATINMAR-SIMVASTATINMINT-SIMVASTATINMYLAN-SIMVASTATINPMS-SIMVASTATINRAN-SIMVASTATINSIMVASTATINSIMVASTATINTEVA-SIMVASTATINZOCOR
APO-SIMVASTATINAURO-SIMVASTATINJAMP-SIMVASTATINMAR-SIMVASTATINMINT-SIMVASTATINMYLAN-SIMVASTATINPMS-SIMVASTATINRAN-SIMVASTATINSIMVASTATINSIMVASTATINTEVA-SIMVASTATINZOCOR
APO-SIMVASTATINAURO-SIMVASTATINJAMP-SIMVASTATINMAR-SIMVASTATINMINT-SIMVASTATINMYLAN-SIMVASTATINPMS-SIMVASTATINRAN-SIMVASTATINSIMVASTATINSIMVASTATINTEVA-SIMVASTATIN
MINT-CLONIDINETEVA-CLONIDINE
MINT-CLONIDINETEVA-CLONIDINE
APXAURJPCMARMPIMYPPMSRANSNSSIVTEVMFC
APXAURJPCMARMPIMYPPMSRANSNSSIVTEVMFC
APXAURJPCMARMPIMYPPMSRANSNSSIVTEV
MPITEV
MPITEV
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
ANTILIPEMIC AGENTS
HYPOTENSIVE AGENTS
24
24
:00
:00
24:06.08
24:08.16
0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 2.7521
0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 2.7521
0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501 0.2501
0.1358 0.1358
0.2424 0.2424
47 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$$$$
$$$$$$$$$$$$
$$$$$$$$$$$
$$
$$
(HMG-COA REDUCTASE INHIBITORS)
(CENTRAL ALPHA-AGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
METHYLDOPA
HYDRALAZINE HCL
MINOXIDIL
ETHACRYNIC ACID
FUROSEMIDE
125 MG ORAL TABLET
250 MG ORAL TABLET
500 MG ORAL TABLET
10 MG ORAL TABLET
25 MG ORAL TABLET
50 MG ORAL TABLET
2.5 MG ORAL TABLET
10 MG ORAL TABLET
25 MG ORAL TABLET
20 MG ORAL TABLET
40 MG ORAL TABLET
00000360252
00000360260
00000426830
0000044161900002457865
0000044162700002457873
0000044163500002457881
00000514497
00000514500
00002258528
000003967880000235142000000337730
000003621660000235143900000337749
METHYLDOPA
METHYLDOPA
METHYLDOPA
APO-HYDRALAZINEJAMP-HYDRALAZINE
APO-HYDRALAZINEJAMP-HYDRALAZINE
APO-HYDRALAZINEJAMP-HYDRALAZINE
LONITEN
LONITEN
EDECRIN
APO-FUROSEMIDEFUROSEMIDETEVA-FUROSEMIDE
APO-FUROSEMIDEFUROSEMIDETEVA-FUROSEMIDE
AAP
AAP
AAP
APXJPC
APXJPC
APXJPC
PFI
PFI
VCL
APXSNSTEV
APXSNSTEV
(LOOP DIURETICS)
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
HYPOTENSIVE AGENTS
HYPOTENSIVE AGENTS
HYPOTENSIVE AGENTS
24
24
24
:00
:00
:00
24:08.16
24:08.20
24:08.24.08
0.1030
0.1542
0.2642
0.0709 0.0709
0.1218 0.1218
0.1912 0.1912
0.4584
1.0104
0.9192
0.0373 0.0373 0.0373
0.0746 0.0746 0.0746
48 EFFECTIVE APRIL 1, 2018
$
$
$
$$
$$
$$
$
$
$
$$$
$$$
(CENTRAL ALPHA-AGONISTS)
(DIRECT VASODILATORS)
DIURETICS
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
FUROSEMIDE
OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE
80 MG ORAL TABLET
500 MG ORAL TABLET
10 MG / ML ORAL SOLUTION
10 MG / ML INJECTION
20 MG ORAL TABLET
40 MG ORAL TABLET
20 MG * 12.5 MG ORAL TABLET
40 MG * 12.5 MG ORAL TABLET
000007075700000235144700000765953
00002224755
00002224720
0000052703300002382539
0000244219100002453452000024438640000246164100002442515000024613070000244341400002318660
0000244220500002453460000024438720000246166800002442523000024613150000244342200002318679
000024431120000245360600002319616
000024431200000245361400002319624
APO-FUROSEMIDEFUROSEMIDETEVA-FUROSEMIDE
LASIX SPECIAL
LASIX
FUROSEMIDEFUROSEMIDE INJECTION SDZ
ACT OLMESARTANAPO-OLMESARTANAURO-OLMESARTANJAMP-OLMESARTANMED-OLMESARTANPMS-OLMESARTANSANDOZ OLMESARTANOLMETEC
ACT OLMESARTANAPO-OLMESARTANAURO-OLMESARTANJAMP-OLMESARTANMED-OLMESARTANPMS-OLMESARTANSANDOZ OLMESARTANOLMETEC
ACT OLMESARTAN HCTAPO-OLMESARTAN/HCTZOLMETEC PLUS
ACT OLMESARTAN HCTAPO-OLMESARTAN/HCTZOLMETEC PLUS
APXSNSTEV
SAV
SAV
SDZSDZ
APHAPXAURJPCGMPPMSSDZMFC
APHAPXAURJPCGMPPMSSDZMFC
APHAPXMFC
APHAPXMFC
(LOOP DIURETICS)
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
HYPOTENSIVE AGENTS
HYPOTENSIVE AGENTS
24
24
:00
:00
24:08.24.08
24:08.44.08
0.1220 0.1220 0.1220
3.2710
0.3082
0.8650 0.8650
0.3019 0.3019 0.3019 0.3019 0.3019 0.3019 0.3019 1.1054
0.3019 0.3019 0.3019 0.3019 0.3019 0.3019 0.3019 1.1054
0.6038 0.6038 1.1054
0.6038 0.6038 1.1054
49 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$
$
$
$$
$$$$$$$$
$$$$$$$$
$$$
$$$
DIURETICS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE
ISOSORBIDE DINITRATE
ISOSORBIDE-5-MONONITRATE
NITROGLYCERIN
40 MG * 25 MG ORAL TABLET
10 MG ORAL TABLET
30 MG ORAL TABLET
5 MG ORAL SUBLINGUAL TABLET
60 MG ORAL EXTENDED-RELEASE TABLET
0.3 MG ORAL SUBLINGUAL TABLET
0.6 MG ORAL SUBLINGUAL TABLET
0.4 MG / DOSE SUBLINGUAL METERED DOSE SPRAY
2 % TOPICAL OINTMENT
0.2 MG/HR TRANSDERMAL PATCH
0.4 MG/HR TRANSDERMAL PATCH
000024431390000245362200002319632
00000441686
00000441694
00000670944
000022728300000230128800002126559
00000037613
00000037621
00002393433000022435880000223899800002231441
00001926454
0000240744200001911910000022307320000216280600000584223
0000240745000001911902000022307330000216352700000852384
ACT OLMESARTAN HCTAPO-OLMESARTAN/HCTZOLMETEC PLUS
ISDN
ISDN
ISDN
APO-ISMNPMS-ISMNIMDUR
NITROSTAT
NITROSTAT
APO-NITROGLYCERINMYLAN-NITRORHO-NITRO PUMPSPRAYNITROLINGUAL PUMPSPRAY
NITROL
MYLAN-NITRO PATCHNITRO-DUR 0.2TRINIPATCH 0.2MINITRAN 0.2TRANSDERM-NITRO 0.2
MYLAN-NITRO PATCHNITRO-DUR 0.4TRINIPATCH 0.4MINITRAN 0.4TRANSDERM-NITRO 0.4
APHAPXMFC
AAP
AAP
AAP
APXPMSAZC
PFI
PFI
APXMYPSDZSAV
PAL
MYPMFCPALVCLNOV
MYPMFCPALVCLNOV
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
HYPOTENSIVE AGENTS
VASODILATING AGENTS
24
24
:00
:00
24:08.44.08
24:12.08
0.6038 0.6038 1.1054
0.0380
0.0892
0.0646
0.3523 0.3523 0.7350
0.1501
0.1501
0.0421 0.0421 0.0421 0.0762
0.6948
0.4463 0.6062 0.6286 0.6385 0.7190
0.4938 0.6845 0.7099 0.7215 0.8120
50 EFFECTIVE APRIL 1, 2018
$$$
$
$
$
$$$
$
$
$$$$
$
$$$$$
$$$$$
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
(NITRATES AND NITRITES)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
NITROGLYCERIN
ALPROSTADIL
DIPYRIDAMOLE
DOXAZOSIN MESYLATE
PRAZOSIN HCL
0.6 MG/HR TRANSDERMAL PATCH
0.8 MG/HR TRANSDERMAL PATCH
500 MCG / ML INJECTION
25 MG ORAL TABLET
50 MG ORAL TABLET
75 MG ORAL TABLET
1 MG (BASE) ORAL TABLET
2 MG (BASE) ORAL TABLET
4 MG (BASE) ORAL TABLET
1 MG (BASE) ORAL TABLET
2 MG (BASE) ORAL TABLET
5 MG (BASE) ORAL TABLET
0000240746900001911929000022307340000216353500002046156
0000240747700002011271
00000559253
00000895644
00000895652
00000895660
0000224058800002242728
0000224058900002242729
0000224059000002242730
0000088280100001934198
0000088282800001934201
0000088283600001934228
MYLAN-NITRO PATCHNITRO-DUR 0.6TRINIPATCH 0.6MINITRAN 0.6TRANSDERM-NITRO 0.6
MYLAN-NITRO PATCHNITRO-DUR 0.8
PROSTIN VR
APO-DIPYRIDAMOLE (FC)
APO-DIPYRIDAMOLE (FC)
APO-DIPYRIDAMOLE (FC)
APO-DOXAZOSINTEVA-DOXAZOSIN
APO-DOXAZOSINTEVA-DOXAZOSIN
APO-DOXAZOSINTEVA-DOXAZOSIN
APO-PRAZOTEVA-PRAZOSIN
APO-PRAZOTEVA-PRAZOSIN
APO-PRAZOTEVA-PRAZOSIN
MYPMFCPALVCLNOV
MYPMFC
PFI
APX
APX
APX
APXTEV
APXTEV
APXTEV
APXTEV
APXTEV
APXTEV
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
VASODILATING AGENTS
VASODILATING AGENTS
ALPHA-ADRENERGIC BLOCKING AGENTS
24
24
24
:00
:00
:00
24:12.08
24:12.92
24:20
0.4938 0.6845 0.7099 0.7219 0.8120
0.8743 1.1872
261.8930
0.2633
0.3685
0.4963
0.1416 0.1416
0.1699 0.1699
0.2209 0.2209
0.2743 0.2743
0.3725 0.3725
0.5121 0.5121
51 EFFECTIVE APRIL 1, 2018
UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$
$$
$
$
$
$
$$
$$
$$
$$
$$
$$
(NITRATES AND NITRITES)
(MISCELLANEOUS VASODILATING AGENTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
TAMSULOSIN HCL
TERAZOSIN HCL
ACEBUTOLOL HCL
0.4 MG ORAL EXTENDED-RELEASE TABLET
0.4 MG ORAL SUSTAINED-RELEASE CAPSULE
1 MG (BASE) ORAL TABLET
2 MG (BASE) ORAL TABLET
5 MG (BASE) ORAL TABLET
10 MG (BASE) ORAL TABLET
100 MG (BASE) ORAL TABLET
200 MG (BASE) ORAL TABLET
000023624060000234020800002427117000024296670000236824200002270102
0000229426500002319217
00002234502000022435180000235047500002230805
00002234503000022435190000235048300002230806
00002234504000022435200000235049100002230807
00002234505000022435210000235050500002230808
0000228624600002147602000022377210000220451700001926543
0000228625400002147610000022377220000220452500001926551
APO-TAMSULOSIN CRSANDOZ TAMSULOSIN CRTAMSULOSIN CRTAMSULOSIN CRTEVA-TAMSULOSIN CRFLOMAX CR
RATIO-TAMSULOSINSANDOZ TAMSULOSIN
APO-TERAZOSINPMS-TERAZOSINTERAZOSINTEVA-TERAZOSIN
APO-TERAZOSINPMS-TERAZOSINTERAZOSINTEVA-TERAZOSIN
APO-TERAZOSINPMS-TERAZOSINTERAZOSINTEVA-TERAZOSIN
APO-TERAZOSINPMS-TERAZOSINTERAZOSINTEVA-TERAZOSIN
ACEBUTOLOLAPO-ACEBUTOLOLMYLAN-ACEBUTOLOLTEVA-ACEBUTOLOLSECTRAL
ACEBUTOLOLAPO-ACEBUTOLOLMYLAN-ACEBUTOLOLTEVA-ACEBUTOLOLSECTRAL
APXSDZSNSSIVTEVBOE
TEVSDZ
APXPMSSNSTEV
APXPMSSNSTEV
APXPMSSNSTEV
APXPMSSNSTEV
SNSAPXMYPTEVSAV
SNSAPXMYPTEVSAV
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
ALPHA-ADRENERGIC BLOCKING AGENTS
BETA-ADRENERGIC BLOCKING AGENTS
24
24
:00
:00
24:20
24:24
0.1500 0.1500 0.1500 0.1500 0.1500 0.6472
0.1500 0.1500
0.1835 0.1835 0.1835 0.1835
0.2333 0.2333 0.2333 0.2333
0.3168 0.3168 0.3168 0.3168
0.4637 0.4637 0.4637 0.4637
0.0787 0.0787 0.0787 0.0787 0.3742
0.1177 0.1177 0.1177 0.1177 0.5615
52 EFFECTIVE APRIL 1, 2018
$$$$$$
$$
$$$$
$$$$
$$$$
$$$$
$$$$$
$$$$$
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
ACEBUTOLOL HCL
ATENOLOL
ATENOLOL/ CHLORTHALIDONE
400 MG (BASE) ORAL TABLET
25 MG ORAL TABLET
50 MG ORAL TABLET
100 MG ORAL TABLET
50 MG * 25 MG ORAL TABLET
100 MG * 25 MG ORAL TABLET
00002286262000021476290000223772300002204533
0000224718200002367556000023719790000236801300002303647000022465810000237396300002266660
000022555450000077368900002238316000024664650000236756400002371987000023680210000214689400002237600000022679850000236864100002039532
000022555530000077369700002238318000024664730000236757200002371995000023680480000214743200002237601000022679930000236866800002039540
000022487630000230291800002049961
000022487640000230292600002049988
ACEBUTOLOLAPO-ACEBUTOLOLMYLAN-ACEBUTOLOLTEVA-ACEBUTOLOL
ATENOLOLJAMP-ATENOLOLMAR-ATENOLOLMINT-ATENOLMYLAN-ATENOLOLPMS-ATENOLOLRAN-ATENOLOLTEVA-ATENOLOL
ACT ATENOLOLAPO-ATENOLATENOLOLATENOLOLJAMP-ATENOLOLMAR-ATENOLOLMINT-ATENOLMYLAN-ATENOLOLPMS-ATENOLOLRAN-ATENOLOLSEPTA-ATENOLOLTENORMIN
ACT ATENOLOLAPO-ATENOLATENOLOLATENOLOLJAMP-ATENOLOLMAR-ATENOLOLMINT-ATENOLMYLAN-ATENOLOLPMS-ATENOLOLRAN-ATENOLOLSEPTA-ATENOLOLTENORMIN
APO-ATENIDONETEVA-ATENOLTHALIDONETENORETIC 50/25
APO-ATENIDONETEVA-ATENOLTHALIDONETENORETIC 100/25
SNSAPXMYPTEV
SIVJPCMARMPIMYPPMSRANTEV
APHAPXSIVSNSJPCMARMPIMYPPMSRANSEPAZC
APHAPXSIVSNSJPCMARMPIMYPPMSRANSEPAZC
APXTEVAZC
APXTEVAZC
CARDIOVASCULAR DRUGS
BETA-ADRENERGIC BLOCKING AGENTS
24:00
24:24
0.2466 0.2466 0.2466 0.2466
0.0521 0.0521 0.0521 0.0521 0.0521 0.0521 0.0521 0.0521
0.1107 0.1107 0.1107 0.1107 0.1107 0.1107 0.1107 0.1107 0.1107 0.1107 0.1107 0.6086
0.1821 0.1821 0.1821 0.1821 0.1821 0.1821 0.1821 0.1821 0.1821 0.1821 0.1821 1.0006
0.3195 0.3195 0.7122
0.5236 0.5236 1.1673
53 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$
$$$$$$$$
$$$$$$$$$$$$
$$$$$$$$$$$$
$$$
$$$
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
BISOPROLOL FUMARATE
CARVEDILOL
LABETALOL HCL
5 MG ORAL TABLET
10 MG ORAL TABLET
3.125 MG ORAL TABLET
6.25 MG ORAL TABLET
12.5 MG ORAL TABLET
25 MG ORAL TABLET
100 MG ORAL TABLET
200 MG ORAL TABLET
0000225613400002383055000023915890000224743900002267470
0000225617700002383063000023915970000224744000002267489
00002247933000024184950000224875200002364913000023688970000224591400002252309
00002247934000024185090000224875300002364921000023689000000224591500002252317
00002247935000024185170000224875400002364948000023689190000224591600002252325
00002247936000024185250000224875500002364956000023689270000224591700002252333
00002106272
00002106280
APO-BISOPROLOLBISOPROLOLBISOPROLOLSANDOZ BISOPROLOLTEVA-BISOPROLOL
APO-BISOPROLOLBISOPROLOLBISOPROLOLSANDOZ BISOPROLOLTEVA-BISOPROLOL
APO-CARVEDILOLAURO-CARVEDILOLCARVEDILOLCARVEDILOLJAMP-CARVEDILOLPMS-CARVEDILOLRATIO-CARVEDILOL
APO-CARVEDILOLAURO-CARVEDILOLCARVEDILOLCARVEDILOLJAMP-CARVEDILOLPMS-CARVEDILOLRATIO-CARVEDILOL
APO-CARVEDILOLAURO-CARVEDILOLCARVEDILOLCARVEDILOLJAMP-CARVEDILOLPMS-CARVEDILOLRATIO-CARVEDILOL
APO-CARVEDILOLAURO-CARVEDILOLCARVEDILOLCARVEDILOLJAMP-CARVEDILOLPMS-CARVEDILOLRATIO-CARVEDILOL
TRANDATE
TRANDATE
APXSIVSNSSDZTEV
APXSIVSNSSDZTEV
APXAURSIVSNSJPCPMSTEV
APXAURSIVSNSJPCPMSTEV
APXAURSIVSNSJPCPMSTEV
APXAURSIVSNSJPCPMSTEV
PAL
PAL
CARDIOVASCULAR DRUGS
BETA-ADRENERGIC BLOCKING AGENTS
24:00
24:24
0.0715 0.0715 0.0715 0.0715 0.0715
0.1044 0.1044 0.1044 0.1044 0.1044
0.2431 0.2431 0.2431 0.2431 0.2431 0.2431 0.2431
0.2431 0.2431 0.2431 0.2431 0.2431 0.2431 0.2431
0.2431 0.2431 0.2431 0.2431 0.2431 0.2431 0.2431
0.2431 0.2431 0.2431 0.2431 0.2431 0.2431 0.2431
0.2911
0.5147
54 EFFECTIVE APRIL 1, 2018
$$$$$
$$$$$
$$$$$$$
$$$$$$$
$$$$$$$
$$$$$$$
$
$
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
METOPROLOL TARTRATE
NADOLOL
PROPRANOLOL HCL
25 MG ORAL TABLET
50 MG ORAL TABLET
100 MG ORAL TABLET
100 MG ORAL SUSTAINED-RELEASE TABLET
200 MG (BASE) ORAL SUSTAINED-RELEASE TABLET
40 MG ORAL TABLET
80 MG ORAL TABLET
160 MG ORAL TABLET
10 MG ORAL TABLET
20 MG ORAL TABLET
40 MG ORAL TABLET
80 MG ORAL TABLET
000022460100000235681300002248855
00000618632000007493540000235682100002350394000024421240000223080300002354187000008426480000064803500000397423
00000618640000007511700000235684800002350408000024421320000223080400002354195000008426560000064804300000397431
000022851690000230339600000658855
000022851770000230341800000534560
00000782505
00000782467
00000782475
00000496480
00000740675
00000496499
00000496502
APO-METOPROLOLJAMP-METOPROLOL-LPMS-METOPROLOL-L
APO-METOPROLOLAPO-METOPROLOL (TYPE L)JAMP-METOPROLOL-LMETOPROLOLMETOPROLOL-LPMS-METOPROLOL-LSANDOZ METOPROLOL (TYPE L)TEVA-METOPROLTEVA-METOPROL (FC)LOPRESOR
APO-METOPROLOLAPO-METOPROLOL (TYPE L)JAMP-METOPROLOL-LMETOPROLOLMETOPROLOL-LPMS-METOPROLOL-LSANDOZ METOPROLOL (TYPE L)TEVA-METOPROLTEVA-METOPROL (FC)LOPRESOR
APO-METOPROLOL SRSANDOZ METOPROLOL SRLOPRESOR SR
APO-METOPROLOL SRSANDOZ METOPROLOL SRLOPRESOR SR
NADOL
NADOL
NADOL
TEVA-PROPRANOLOL
TEVA-PROPRANOLOL
TEVA-PROPRANOLOL
TEVA-PROPRANOLOL
APXJPCPMS
APXAPXJPCSNSSIVPMSSDZTEVTEVNOV
APXAPXJPCSNSSIVPMSSDZTEVTEVNOV
APXSDZNOV
APXSDZNOV
AAP
AAP
AAP
TEV
TEV
TEV
TEV
CARDIOVASCULAR DRUGS
BETA-ADRENERGIC BLOCKING AGENTS
24:00
24:24
0.0643 0.0643 0.0643
0.0624 0.0624 0.0624 0.0624 0.0624 0.0624 0.0624 0.0624 0.0624 0.2960
0.1250 0.1250 0.1250 0.1250 0.1250 0.1250 0.1250 0.1250 0.1250 0.6074
0.1871 0.1871 0.3316
0.3396 0.3396 0.6020
0.4607
0.3788
1.2299
0.0601
0.1034
0.1088
0.1719
55 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$
$$$$$$$$$$
$$$$$$$$$$
$$$
$$$
$
$
$
$
$
$
$
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
SOTALOL HCL
AMLODIPINE BESYLATE
80 MG ORAL TABLET
160 MG ORAL TABLET
2.5 MG (BASE) ORAL TABLET
5 MG (BASE) ORAL TABLET
000022104280000236861700002238326
000021677940000236862500002238327
0000229747700002385783000023571860000229514800002330474
0000229748500002331284000023857910000242921700002273373000023970720000228013200002371715000023626510000227211300002284065000023218580000228438300002357712000022504970000242698600000878928
APO-SOTALOLJAMP-SOTALOLPMS-SOTALOL
APO-SOTALOLJAMP-SOTALOLPMS-SOTALOL
ACT AMLODIPINEAMLODIPINEJAMP-AMLODIPINEPMS-AMLODIPINESANDOZ AMLODIPINE
ACT AMLODIPINEAMLODIPINEAMLODIPINEAMLODIPINEAPO-AMLODIPINEAURO-AMLODIPINEGD-AMLODIPINEMAR-AMLODIPINEMINT-AMLODIPINEMYLAN-AMLODIPINEPMS-AMLODIPINERAN-AMLODIPINESANDOZ AMLODIPINESEPTA-AMLODIPINETEVA-AMLODIPINEVAN-AMLODIPINENORVASC
APXJPCPMS
APXJPCPMS
APHSIVJPCPMSSDZ
APHSNSSIVJPCAPXAURGMDMARMPIMYPPMSRANSDZSEPTEVVANPFI
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
BETA-ADRENERGIC BLOCKING AGENTS
CALCIUM-CHANNEL BLOCKING AGENTS
24
24
:00
:00
24:24
24:28.08
0.2966 0.2966 0.2966
0.1623 0.1623 0.1623
0.0767 0.0767 0.0767 0.0767 0.0767
0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 0.1343 1.4064
56 EFFECTIVE APRIL 1, 2018
$$$
$$$
$$$$$
$$$$$$$$$$$$$$$$$
(DIHYDROPYRIDINES)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
AMLODIPINE BESYLATE
FELODIPINE
NIFEDIPINE
10 MG (BASE) ORAL TABLET
2.5 MG ORAL EXTENDED-RELEASE TABLET
5 MG ORAL EXTENDED-RELEASE TABLET
10 MG ORAL EXTENDED-RELEASE TABLET
20 MG ORAL EXTENDED-RELEASE TABLET
30 MG ORAL EXTENDED-RELEASE TABLET
60 MG ORAL EXTENDED-RELEASE TABLET
5 MG ORAL CAPSULE
10 MG ORAL CAPSULE
000022974930000233129200002385805000024292250000227338100002397080000022801400000235720800002371723000023626780000227212100002284073000023218660000228439100002357720000022505000000242699400000878936
0000245236700002057778
000024523750000228026400000851779
000024523830000228027200000851787
00002237618
0000215590700002349167
0000215599000002321149
00000725110
00000755907
ACT AMLODIPINEAMLODIPINEAMLODIPINEAMLODIPINEAPO-AMLODIPINEAURO-AMLODIPINEGD-AMLODIPINEJAMP-AMLODIPINEMAR-AMLODIPINEMINT-AMLODIPINEMYLAN-AMLODIPINEPMS-AMLODIPINERAN-AMLODIPINESANDOZ AMLODIPINESEPTA-AMLODIPINETEVA-AMLODIPINEVAN-AMLODIPINENORVASC
APO-FELODIPINEPLENDIL
APO-FELODIPINESANDOZ FELODIPINEPLENDIL
APO-FELODIPINESANDOZ FELODIPINEPLENDIL
ADALAT XL
ADALAT XLMYLAN-NIFEDIPINE EXTENDED RELEASE
ADALAT XLMYLAN-NIFEDIPINE EXTENDED RELEASE
NIFEDIPINE
NIFEDIPINE
APHSNSSIVJPCAPXAURGMDJPCMARMPIMYPPMSRANSDZSEPTEVVANPFI
APXAZC
APXSDZAZC
APXSDZAZC
BAI
BAIMYP
BAIMYP
AAP
AAP
CARDIOVASCULAR DRUGS
CALCIUM-CHANNEL BLOCKING AGENTS
24:00
24:28.08
0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 0.1993 2.0528
0.4050 0.5400
0.3565 0.3565 0.7130
0.5350 0.5350 1.0700
1.2864
0.6171 0.6171
0.9374 0.9374
0.3756
0.4979
57 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$$$$$$$$$$
$$
$$$
$$$
$
$$
$$
$
$
(DIHYDROPYRIDINES)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
DILTIAZEM HCL30 MG ORAL TABLET
60 MG ORAL TABLET
120 MG ORAL EXTENDED-RELEASE TABLET
180 MG ORAL EXTENDED-RELEASE TABLET
240 MG ORAL EXTENDED-RELEASE TABLET
300 MG ORAL EXTENDED-RELEASE TABLET
360 MG ORAL EXTENDED-RELEASE TABLET
120 MG ORAL CONTROLLED-DELIVERY CAPSULE
180 MG ORAL CONTROLLED-DELIVERY CAPSULE
240 MG ORAL CONTROLLED-DELIVERY CAPSULE
300 MG ORAL CONTROLLED-DELIVERY CAPSULE
120 MG ORAL EXTENDED-RELEASE CAPSULE
180 MG ORAL EXTENDED-RELEASE CAPSULE
0000077137600000862924
0000077138400000862932
00002256738
00002256746
00002256754
00002256762
00002256770
0000237061100002230997000024459990000224333800002242538
0000237063800002230998000024460060000224333900002242539
0000237064600002230999000024460140000224334000002242540
0000237065400002229526000024460220000224334100002242541
00002370441000022459180000227160500002231150
00002370492000022459190000227161300002231151
APO-DILTIAZTEVA-DILTIAZEM
APO-DILTIAZTEVA-DILTIAZEM
TIAZAC XC
TIAZAC XC
TIAZAC XC
TIAZAC XC
TIAZAC XC
ACT DILTIAZEM CDAPO-DILTIAZ CDDILTIAZEM CDSANDOZ DILTIAZEM CDTEVA-DILTIAZEM CD
ACT DILTIAZEM CDAPO-DILTIAZ CDDILTIAZEM CDSANDOZ DILTIAZEM CDTEVA-DILTIAZEM CD
ACT DILTIAZEM CDAPO-DILTIAZ CDDILTIAZEM CDSANDOZ DILTIAZEM CDTEVA-DILTIAZEM CD
ACT DILTIAZEM CDAPO-DILTIAZ CDDILTIAZEM CDSANDOZ DILTIAZEM CDTEVA-DILTIAZEM CD
ACT DILTIAZEM TSANDOZ DILTIAZEM TTEVA-DILTIAZEM HCL ERTIAZAC
ACT DILTIAZEM TSANDOZ DILTIAZEM TTEVA-DILTIAZEM HCL ERTIAZAC
APXTEV
APXTEV
VCL
VCL
VCL
VCL
VCL
APHAPXSIVSDZTEV
APHAPXSIVSDZTEV
APHAPXSIVSDZTEV
APHAPXSIVSDZTEV
APHSDZVTCVCL
APHSDZVTCVCL
CARDIOVASCULAR DRUGS
CALCIUM-CHANNEL BLOCKING AGENTS
24:00
24:28.92
0.1866 0.1866
0.3273 0.3273
0.8761
1.1641
1.5473
1.5442
1.5449
0.3529 0.3529 0.3529 0.3529 0.3529
0.4684 0.4684 0.4684 0.4684 0.4684
0.6213 0.6213 0.6213 0.6213 0.6213
0.7766 0.7766 0.7766 0.7766 0.7766
0.2133 0.2133 0.2133 0.9217
0.2889 0.2889 0.2889 1.2312
58 EFFECTIVE APRIL 1, 2018
$$
$$
$
$
$
$
$
$$$$$
$$$$$
$$$$$
$$$$$
$$$$
$$$$
(MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
DILTIAZEM HCL
VERAPAMIL HCL
BENAZEPRIL HCL
240 MG ORAL EXTENDED-RELEASE CAPSULE
300 MG ORAL EXTENDED-RELEASE CAPSULE
360 MG ORAL EXTENDED-RELEASE CAPSULE
80 MG ORAL TABLET
120 MG ORAL TABLET
120 MG ORAL SUSTAINED-RELEASE TABLET
180 MG ORAL SUSTAINED-RELEASE TABLET
240 MG ORAL SUSTAINED-RELEASE TABLET
5 MG ORAL TABLET
10 MG ORAL TABLET
20 MG ORAL TABLET
00002370506000022459200000227162100002231152
00002370514000022459210000227164800002231154
00002370522000022459220000227165600002231155
0000078248300002237921
0000078249100002237922
000022468930000221034700001907123
0000245048800001934317
00002246895000024504960000223779100000742554
00002290332
00002290340
0000227391800000885851
ACT DILTIAZEM TSANDOZ DILTIAZEM TTEVA-DILTIAZEM HCL ERTIAZAC
ACT DILTIAZEM TSANDOZ DILTIAZEM TTEVA-DILTIAZEM HCL ERTIAZAC
ACT DILTIAZEM TSANDOZ DILTIAZEM TTEVA-DILTIAZEM HCL ERTIAZAC
APO-VERAPMYLAN-VERAPAMIL
APO-VERAPMYLAN-VERAPAMIL
APO-VERAP SRMYLAN-VERAPAMIL SRISOPTIN SR
MYLAN-VERAPAMIL SRISOPTIN SR
APO-VERAP SRMYLAN-VERAPAMIL SRPMS-VERAPAMIL SRISOPTIN SR
BENAZEPRIL
BENAZEPRIL
BENAZEPRILLOTENSIN
APHSDZVTCVCL
APHSDZVTCVCL
APHSDZVTCVCL
APXMYP
APXMYP
APXMYPBGP
MYPBGP
APXMYPPMSBGP
AAP
AAP
AAPNOV
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
CALCIUM-CHANNEL BLOCKING AGENTS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24
24
:00
:00
24:28.92
24:32.04
0.3832 0.3832 0.3832 1.6331
0.4719 0.4719 0.4719 2.0454
0.5778 0.5778 0.5778 2.4625
0.2735 0.2735
0.4250 0.4250
0.5078 0.5078 1.4667
0.5204 1.6562
0.5075 0.5075 0.5075 2.2086
0.7232
0.9639
0.9814 1.1257
59 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$
$$$$
$$$$
$$
$$
$$$
$$
$$$$
$
$
$$
(MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS)
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
CAPTOPRIL
CILAZAPRIL
CILAZAPRIL/ HYDROCHLOROTHIAZIDE
ENALAPRIL MALEATE
12.5 MG ORAL TABLET
25 MG ORAL TABLET
50 MG ORAL TABLET
100 MG ORAL TABLET
1 MG ORAL TABLET
2.5 MG ORAL TABLET
5 MG ORAL TABLET
5 MG * 12.5 MG ORAL TABLET
2.5 MG ORAL TABLET
5 MG ORAL TABLET
00001942964
00001942972
00001942980
00001942999
0000229113400002283778
000022911420000228378600001911473
000022911500000228379400001911481
000022849870000231373100002181479
00002291878000020200250000240065000002442957000023000360000235223000002299933
000022918860000201988400002400669000024429650000230004400002352249000022999410000223300500000708879
TEVA-CAPTOPRIL
TEVA-CAPTOPRIL
TEVA-CAPTOPRIL
TEVA-CAPTOPRIL
APO-CILAZAPRILMYLAN-CILAZAPRIL
APO-CILAZAPRILMYLAN-CILAZAPRILINHIBACE
APO-CILAZAPRILMYLAN-CILAZAPRILINHIBACE
APO-CILAZAPRIL/HCTZNOVO-CILAZAPRIL/HCTZINHIBACE PLUS
ACT ENALAPRILAPO-ENALAPRILENALAPRILENALAPRILMYLAN-ENALAPRILRAN-ENALAPRILSANDOZ ENALAPRIL
ACT ENALAPRILAPO-ENALAPRILENALAPRILENALAPRILMYLAN-ENALAPRILRAN-ENALAPRILSANDOZ ENALAPRILTEVA-ENALAPRILVASOTEC
TEV
TEV
TEV
TEV
APXMYP
APXMYPHLR
APXMYPHLR
APXTEVHLR
APHAPXSNSSIVMYPRANSDZ
APHAPXSNSSIVMYPRANSDZTEVMFC
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.04
0.1113
0.1575
0.2935
0.5458
0.1557 0.1557
0.1795 0.1795 0.8589
0.2085 0.2085 0.9978
0.4170 0.4170 0.9975
0.1863 0.1863 0.1863 0.1863 0.1863 0.1863 0.1863
0.2203 0.2203 0.2203 0.2203 0.2203 0.2203 0.2203 0.2203 1.0016
60 EFFECTIVE APRIL 1, 2018
$
$
$
$
$$
$$$
$$$
$$$
$$$$$$$
$$$$$$$$$
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
ENALAPRIL MALEATE
ENALAPRIL MALEATE/ HYDROCHLOROTHIAZIDE
FOSINOPRIL SODIUM
10 MG ORAL TABLET
20 MG ORAL TABLET
5 MG * 12.5 MG ORAL TABLET
10 MG * 25 MG ORAL TABLET
10 MG ORAL TABLET
20 MG ORAL TABLET
000022918940000201989200002400677000024429730000230005200002352257000022999680000223300600000670901
000022919080000201990600002400685000024429810000230006000002352265000022999760000223300700000670928
00002352923
0000235293100000657298
00002266008000024593880000233100400002247802
00002266016000024593960000233101200002247803
ACT ENALAPRILAPO-ENALAPRILENALAPRILENALAPRILMYLAN-ENALAPRILRAN-ENALAPRILSANDOZ ENALAPRILTEVA-ENALAPRILVASOTEC
ACT ENALAPRILAPO-ENALAPRILENALAPRILENALAPRILMYLAN-ENALAPRILRAN-ENALAPRILSANDOZ ENALAPRILTEVA-ENALAPRILVASOTEC
ENALAPRIL MALEATE/HCTZ
ENALAPRIL MALEATE/HCTZVASERETIC
APO-FOSINOPRILFOSINOPRILJAMP-FOSINOPRILTEVA-FOSINOPRIL
APO-FOSINOPRILFOSINOPRILJAMP-FOSINOPRILTEVA-FOSINOPRIL
APHAPXSNSSIVMYPRANSDZTEVMFC
APHAPXSNSSIVMYPRANSDZTEVMFC
AAP
AAPMFC
APXSNSJPCTEV
APXSNSJPCTEV
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.04
0.2647 0.2647 0.2647 0.2647 0.2647 0.2647 0.2647 0.2647 1.2036
0.3195 0.3195 0.3195 0.3195 0.3195 0.3195 0.3195 0.3195 1.4525
0.7492
1.0741 1.2398
0.2177 0.2177 0.2177 0.2177
0.2619 0.2619 0.2619 0.2619
61 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$
$$$$$$$$$
$
$$
$$$$
$$$$
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
LISINOPRIL
LISINOPRIL/ HYDROCHLOROTHIAZIDE
5 MG ORAL TABLET
10 MG ORAL TABLET
20 MG ORAL TABLET
10 MG * 12.5 MG ORAL TABLET
20 MG * 12.5 MG ORAL TABLET
20 MG * 25 MG ORAL TABLET
10 MG * 12.5 MG ORAL TABLET
00002217481000023944720000227144300002361531000023862320000229423000002289199000022850610000228511800002049333
00002217503000023944800000236155800002386240000022942490000228920200002285088000022851260000204937600000839396
0000221751100002394499000023615660000238625900002274868000022942570000228922900002285096000022851340000204938400000839418
00002362945000023023650000230176800002103729
00002362953000023023730000230177600002045737
00002362961000023023810000230178400002045729
00002302136
APO-LISINOPRILAURO-LISINOPRILCO LISINOPRILJAMP-LISINOPRILLISINOPRILRAN-LISINOPRILSANDOZ LISINOPRILTEVA-LISINOPRIL (TYPE P)TEVA-LISINOPRIL (TYPE Z)ZESTRIL
APO-LISINOPRILAURO-LISINOPRILJAMP-LISINOPRILLISINOPRILRAN-LISINOPRILSANDOZ LISINOPRILTEVA-LISINOPRIL (TYPE P)TEVA-LISINOPRIL (TYPE Z)ZESTRILPRINIVIL
APO-LISINOPRILAURO-LISINOPRILJAMP-LISINOPRILLISINOPRILMYLAN-LISINOPRILRAN-LISINOPRILSANDOZ LISINOPRILTEVA-LISINOPRIL (TYPE P)TEVA-LISINOPRIL (TYPE Z)ZESTRILPRINIVIL
LISINOPRIL/HCTZ (TYPE Z)SANDOZ LISINOPRIL HCTTEVA-LISINOPRIL/HCTZ (TYPE Z)ZESTORETIC
LISINOPRIL/HCTZ (TYPE Z)SANDOZ LISINOPRIL HCTTEVA-LISINOPRIL/HCTZ (TYPE Z)ZESTORETIC
LISINOPRIL/HCTZ (TYPE Z)SANDOZ LISINOPRIL HCTTEVA-LISINOPRIL/HCTZ (TYPE Z)ZESTORETIC
TEVA-LISINOPRIL/HCTZ (TYPE P)
APXAURAPHJPCSIVRANSDZTEVTEVAZC
APXAURJPCSIVRANSDZTEVTEVAZCMFC
APXAURJPCSIVMYPRANSDZTEVTEVAZCMFC
SNSSDZTEVAZC
SNSSDZTEVAZC
SNSSDZTEVAZC
TEV
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.04
0.1347 0.1347 0.1347 0.1347 0.1347 0.1347 0.1347 0.1347 0.1347 0.5710
0.1619 0.1619 0.1619 0.1619 0.1619 0.1619 0.1619 0.1619 0.6861 0.7690
0.1945 0.1945 0.1945 0.1945 0.1945 0.1945 0.1945 0.1945 0.1945 0.8241 0.9247
0.2083 0.2083 0.2083 0.9286
0.2503 0.2503 0.2503 1.1159
0.2503 0.2503 0.2503 1.1159
0.4319
62 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$
$$$$$$$$$$
$$$$$$$$$$$
$$$$
$$$$
$$$$
$
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
LISINOPRIL/ HYDROCHLOROTHIAZIDE
PERINDOPRIL ERBUMINE
PERINDOPRIL ERBUMINE/ INDAPAMIDE HEMIHYDRATE
QUINAPRIL
QUINAPRIL/ HYDROCHLOROTHIAZIDE
20 MG * 12.5 MG ORAL TABLET
20 MG * 25 MG ORAL TABLET
2 MG ORAL TABLET
4 MG ORAL TABLET
8 MG ORAL TABLET
4 MG * 1.25 MG ORAL TABLET
8 MG * 2.5 MG ORAL TABLET
5 MG (BASE) ORAL TABLET
10 MG (BASE) ORAL TABLET
20 MG (BASE) ORAL TABLET
40 MG (BASE) ORAL TABLET
10 MG (BASE) * 12.5 MG ORAL TABLET
20 MG (BASE) * 12.5 MG ORAL TABLET
20 MG * 25 MG ORAL TABLET
00002302144
00002302152
00002123274
00002123282
00002246624
00002246569
00002321653
000022484990000229098700001947664
000022485000000229099500001947672
000022485010000229100200001947680
000022485020000229101000001947699
0000240876700002237367
0000240877500002237368
0000240878300002237369
TEVA-LISINOPRIL/HCTZ (TYPE P)
TEVA-LISINOPRIL/HCTZ (TYPE P)
COVERSYL
COVERSYL
COVERSYL
COVERSYL PLUS
COVERSYL PLUS HD
APO-QUINAPRILGD-QUINAPRILACCUPRIL
APO-QUINAPRILGD-QUINAPRILACCUPRIL
APO-QUINAPRILGD-QUINAPRILACCUPRIL
APO-QUINAPRILGD-QUINAPRILACCUPRIL
APO-QUINAPRIL/HCTZACCURETIC 10/12.5
APO-QUINAPRIL/HCTZACCURETIC 20/12.5
APO-QUINAPRIL/HCTZACCURETIC 20/25
TEV
TEV
SEV
SEV
SEV
SEV
SEV
APXGMDPFI
APXGMDPFI
APXGMDPFI
APXGMDPFI
APXPFI
APXPFI
APXPFI
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.04
0.2629
0.6429
0.6820
0.8539
1.1956
1.0292
1.1956
0.2321 0.2321 0.9514
0.2321 0.2321 0.9514
0.2321 0.2321 0.9514
0.2321 0.2321 0.9514
0.6865 0.9610
0.6865 0.9610
0.6512 0.9203
63 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$
$
$
$
$
$
$
$$$
$$$
$$$
$$$
$$
$$
$$
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
RAMIPRIL1.25 MG ORAL CAPSULE/TABLET
2.5 MG ORAL CAPSULE/TABLET
5 MG ORAL CAPSULE/TABLET
10 MG ORAL CAPSULE/TABLET
00002295482000022515150000238738700002331101000024204570000229536900002308363000023105030000243886000002221829
000022515310000238739500002331128000024204650000242130500002247917000022879270000237484600002310511000022479450000243887900002221837
00002295504000022515740000238740900002331136000024204730000242131300002247918000022879350000237485400002310538000022479460000243888700002221845
000022515820000238741700002331144000024204810000242132100002247919000022879430000237486200002310546000022479470000243889500002221853
ACT RAMIPRIL (CAPSULE)APO-RAMIPRIL (CAPSULE)AURO-RAMIPRIL (CAPSULE)JAMP-RAMIPRIL (CAPSULE)MAR-RAMIPRIL (CAPSULE)PMS-RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAN-RAMIPRIL (CAPSULE)VAN-RAMIPRIL (CAPSULE)ALTACE (CAPSULE)
APO-RAMIPRIL (CAPSULE)AURO-RAMIPRIL (CAPSULE)JAMP-RAMIPRIL (CAPSULE)MAR-RAMIPRIL (CAPSULE)MINT-RAMIPRIL (CAPSULE)PMS-RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAN-RAMIPRIL (CAPSULE)TEVA-RAMIPRIL (CAPSULE)VAN-RAMIPRIL (CAPSULE)ALTACE (CAPSULE)
ACT RAMIPRIL (CAPSULE)APO-RAMIPRIL (CAPSULE)AURO-RAMIPRIL (CAPSULE)JAMP-RAMIPRIL (CAPSULE)MAR-RAMIPRIL (CAPSULE)MINT-RAMIPRIL (CAPSULE)PMS-RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAN-RAMIPRIL (CAPSULE)TEVA-RAMIPRIL (CAPSULE)VAN-RAMIPRIL (CAPSULE)ALTACE (CAPSULE)
APO-RAMIPRIL (CAPSULE)AURO-RAMIPRIL (CAPSULE)JAMP-RAMIPRIL (CAPSULE)MAR-RAMIPRIL (CAPSULE)MINT-RAMIPRIL (CAPSULE)PMS-RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAMIPRIL (CAPSULE)RAN-RAMIPRIL (CAPSULE)TEVA-RAMIPRIL (CAPSULE)VAN-RAMIPRIL (CAPSULE)ALTACE (CAPSULE)
APHAPXAURJPCMARPMSSIVRANVANVCL
APXAURJPCMARMPIPMSSIVSNSRANTEVVANVCL
APHAPXAURJPCMARMPIPMSSIVSNSRANTEVVANVCL
APXAURJPCMARMPIPMSSIVSNSRANTEVVANVCL
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.04
0.0708 0.0708 0.0708 0.0708 0.0708 0.0708 0.0708 0.0708 0.0708 0.7512
0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.8476
0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.0817 0.8690
0.1034 0.1034 0.1034 0.1034 0.1034 0.1034 0.1034 0.1034 0.1034 0.1034 0.1034 1.1025
64 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$
$$$$$$$$$$$$
$$$$$$$$$$$$$
$$$$$$$$$$$$
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
RAMIPRIL/ HYDROCHLOROTHIAZIDE
TRANDOLAPRIL
2.5 MG * 12.5 MG ORAL TABLET
5 MG * 12.5 MG ORAL TABLET
5 MG * 25 MG ORAL TABLET
10 MG * 12.5 MG ORAL TABLET
10 MG * 25 MG ORAL TABLET
0.5 MG ORAL CAPSULE
1 MG ORAL CAPSULE
2 MG ORAL CAPSULE
4 MG ORAL CAPSULE
00002283131
00002283158
00002283174
0000234215400002283166
0000234217000002283182
00002231457
00002231459
00002231460
00002239267
ALTACE HCT
ALTACE HCT
ALTACE HCT
PMS-RAMIPRIL-HCTZALTACE HCT
PMS-RAMIPRIL-HCTZALTACE HCT
MAVIK
MAVIK
MAVIK
MAVIK
VCL
VCL
VCL
PMSVCL
PMSVCL
BGP
BGP
BGP
BGP
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.04
0.3048
0.3897
0.3897
0.2765 0.5093
0.2765 0.5093
0.2790
0.7046
0.8098
0.9990
65 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$
$
$
$$
$$
$
$
$
$
(ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
CANDESARTAN CILEXETIL8 MG ORAL TABLET
16 MG ORAL TABLET
32 MG ORAL TABLET
000023765390000236535900002388707000023889280000237927900002386518000023791390000239119800002380692000023269650000236631200002239091
000023765470000236536700002388715000023889360000237928700002386526000023791470000239120100002380706000023269730000236632000002239092
0000237655500002399105000024358450000237929500002386534000023791550000239122800002380714000024173400000236633900002311658
ACT CANDESARTANAPO-CANDESARTANCANDESARTANCANDESARTANCANDESARTAN CILEXETILJAMP-CANDESARTANMYLAN-CANDESARTANPMS-CANDESARTANRAN-CANDESARTANSANDOZ CANDESARTANTEVA-CANDESARTANATACAND
ACT CANDESARTANAPO-CANDESARTANCANDESARTANCANDESARTANCANDESARTAN CILEXETILJAMP-CANDESARTANMYLAN-CANDESARTANPMS-CANDESARTANRAN-CANDESARTANSANDOZ CANDESARTANTEVA-CANDESARTANATACAND
ACT CANDESARTANAPO-CANDESARTANCANDESARTANCANDESARTAN CILEXETILJAMP-CANDESARTANMYLAN-CANDESARTANPMS-CANDESARTANRAN-CANDESARTANSANDOZ CANDESARTANTEVA-CANDESARTANATACAND
APHAPXSIVSNSAHIJPCMYPPMSRANSDZTEVAZC
APHAPXSIVSNSAHIJPCMYPPMSRANSDZTEVAZC
APHAPXSNSAHIJPCMYPPMSRANSDZTEVAZC
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 1.2490
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 1.2490
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 1.2490
66 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$$$
$$$$$$$$$$$$
$$$$$$$$$$$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
CANDESARTAN CILEXETIL/ HYDROCHLOROTHIAZIDE
EPROSARTAN MESYLATE
EPROSARTAN MESYLATE/ HYDROCHLOROTHIAZIDE
16 MG * 12.5 MG ORAL TABLET
32 MG * 12.5 MG ORAL TABLET
32 MG * 25 MG ORAL TABLET
400 MG (BASE) ORAL TABLET
600 MG (BASE) ORAL TABLET
600 MG * 12.5 MG ORAL TABLET
0000236786600002421038000023948120000239480400002391295000023279020000239554100002244021
0000239512600002421046000024207320000239556800002332922
00002395134000024210540000242074000002332957
00002240432
00002243942
00002253631
APO-CANDESARTAN/HCTZAURO-CANDESARTAN HCTCANDESARTAN HCTCANDESARTAN/HCTZPMS-CANDESARTAN HCTZSANDOZ CANDESARTAN PLUSTEVA-CANDESARTAN/HCTZATACAND PLUS
APO-CANDESARTAN/HCTZAURO-CANDESARTAN HCTSANDOZ CANDESARTAN PLUSTEVA-CANDESARTAN/HCTZATACAND PLUS
APO-CANDESARTAN/HCTZAURO-CANDESARTAN HCTSANDOZ CANDESARTAN PLUSATACAND PLUS
TEVETEN
TEVETEN
TEVETEN PLUS
APXAURSIVSNSPMSSDZTEVAZC
APXAURSDZTEVAZC
APXAURSDZAZC
BGP
BGP
BGP
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.2156 0.2156 0.2156 0.2156 0.2156 0.2156 0.2156 1.2670
0.2156 0.2156 0.2156 0.2156 1.2670
0.3008 0.3008 0.3008 1.2670
0.7398
1.1311
1.1311
67 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$
$$$$$
$$$$
$
$
$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
IRBESARTAN75 MG ORAL TABLET
150 MG ORAL TABLET
300 MG ORAL TABLET
00002386968000024060980000237234700002385287000024181930000242298000002347296000023170600000240681000002316390000023284610000242708700002237923
00002386976000024061010000237237100002385295000024182070000242299900002347318000023170790000240682900002316404000023284880000242709500002237924
000023869840000240612800002372398000023853090000241821500002423006000023170870000240683700002316412000023284960000242710900002237925
APO-IRBESARTANAURO-IRBESARTANIRBESARTANIRBESARTANJAMP-IRBESARTANMINT-IRBESARTANMYLAN-IRBESARTANPMS-IRBESARTANRAN-IRBESARTANRATIO-IRBESARTANSANDOZ IRBESARTANVAN-IRBESARTANAVAPRO
APO-IRBESARTANAURO-IRBESARTANIRBESARTANIRBESARTANJAMP-IRBESARTANMINT-IRBESARTANMYLAN-IRBESARTANPMS-IRBESARTANRAN-IRBESARTANRATIO-IRBESARTANSANDOZ IRBESARTANVAN-IRBESARTANAVAPRO
APO-IRBESARTANAURO-IRBESARTANIRBESARTANIRBESARTANJAMP-IRBESARTANMINT-IRBESARTANPMS-IRBESARTANRAN-IRBESARTANRATIO-IRBESARTANSANDOZ IRBESARTANVAN-IRBESARTANAVAPRO
APXAURSNSSIVJPCMPIMYPPMSRANTEVSDZVANSAV
APXAURSNSSIVJPCMPIMYPPMSRANTEVSDZVANSAV
APXAURSNSSIVJPCMPIPMSRANTEVSDZVANSAV
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 1.2671
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 1.2671
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 0.2281 1.2671
68 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$$$$
$$$$$$$$$$$$$
$$$$$$$$$$$$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
IRBESARTAN/ HYDROCHLOROTHIAZIDE150 MG * 12.5 MG ORAL TABLET
300 MG * 12.5 MG ORAL TABLET
300 MG * 25 MG ORAL TABLET
000023573990000238764600002447878000023853170000237288600002418223
0000239299200002328518000023305120000233742800002241818
000023574020000238765400002447886000023853250000237289400002418231
0000239301800002328526000023305200000233743600002241819
000023574100000238766200002447894000023853330000237290800002418258
00002393026000023285340000233053900002337444
ACT IRBESARTAN/HCTAPO-IRBESARTAN/HCTZAURO-IRBESARTAN HCTIRBESARTAN HCTIRBESARTAN/HCTZJAMP-IRBESARTAN-HYDROCHLOROTHIAZIDEMINT-IRBESARTAN/HCTZPMS-IRBESARTAN-HCTZRATIO-IRBESARTAN HCTZSANDOZ IRBESARTAN HCTAVALIDE 150/12.5
ACT IRBESARTAN/HCTAPO-IRBESARTAN/HCTZAURO-IRBESARTAN HCTIRBESARTAN HCTIRBESARTAN/HCTZJAMP-IRBESARTAN-HYDROCHLOROTHIAZIDEMINT-IRBESARTAN/HCTZPMS-IRBESARTAN-HCTZRATIO-IRBESARTAN HCTZSANDOZ IRBESARTAN HCTAVALIDE 300/12.5
ACT IRBESARTAN/HCTAPO-IRBESARTAN/HCTZAURO-IRBESARTAN HCTIRBESARTAN HCTIRBESARTAN/HCTZJAMP-IRBESARTAN-HYDROCHLOROTHIAZIDEMINT-IRBESARTAN/HCTZPMS-IRBESARTAN-HCTZRATIO-IRBESARTAN HCTZSANDOZ IRBESARTAN HCT
APHAPXAURSIVSNSJPC
MPIPMSTEVSDZSAV
APHAPXAURSIVSNSJPC
MPIPMSTEVSDZSAV
APHAPXAURSIVSNSJPC
MPIPMSTEVSDZ
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281
0.2281 0.2281 0.2281 0.2281 1.2671
0.2281 0.2281 0.2281 0.2281 0.2281 0.2281
0.2281 0.2281 0.2281 0.2281 1.2671
0.2184 0.2184 0.2184 0.2184 0.2184 0.2184
0.2184 0.2184 0.2184 0.2184
69 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$
$$$$$
$$$$$$
$$$$$
$$$$$$
$$$$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
LOSARTAN POTASSIUM25 MG ORAL TABLET
50 MG ORAL TABLET
100 MG ORAL TABLET
00002379058000024033230000244596400002398834000023887900000240573300002313332000024249670000238083800002182815
0000235483700002353504000024033310000244597200002398842000023888040000240574100002313340000024249750000235796800002182874
0000235484500002353512000024033580000244598000002398850000023888120000240576800002313359000024249830000235797600002182882
APO-LOSARTANAURO-LOSARTANBIO-LOSARTANJAMP-LOSARTANLOSARTANMINT-LOSARTANSANDOZ LOSARTANSEPTA-LOSARTANTEVA-LOSARTANCOZAAR
ACT LOSARTANAPO-LOSARTANAURO-LOSARTANBIO-LOSARTANJAMP-LOSARTANLOSARTANMINT-LOSARTANSANDOZ LOSARTANSEPTA-LOSARTANTEVA-LOSARTANCOZAAR
ACT LOSARTANAPO-LOSARTANAURO-LOSARTANBIO-LOSARTANJAMP-LOSARTANLOSARTANMINT-LOSARTANSANDOZ LOSARTANSEPTA-LOSARTANTEVA-LOSARTANCOZAAR
APXAURBMDJPCSIVMPISDZSEPTEVMFC
APHAPXAURBMDJPCSIVMPISDZSEPTEVMFC
APHAPXAURBMDJPCSIVMPISDZSEPTEVMFC
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 1.3663
0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 1.3663
0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 0.1616 1.3663
70 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$
$$$$$$$$$$$
$$$$$$$$$$$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
LOSARTAN POTASSIUM/ HYDROCHLOROTHIAZIDE50 MG * 12.5 MG ORAL TABLET
100 MG * 12.5 MG ORAL TABLET
100 MG * 25 MG ORAL TABLET
000023712350000242364200002408244000023889600000242764800002389657000023780780000239222400002313375000024285390000235826300002230047
00002371243000024236500000238897900002427656000023896650000237808600002392232000023624490000237714400002297841
000023712510000242366900002408252000023889870000242766400002389673000023780940000239224000002313383000024285470000237715200002241007
APO-LOSARTAN/HCTZAURO-LOSARTAN HCTJAMP-LOSARTAN HCTZLOSARTAN/HCTLOSARTAN/HCTZMINT-LOSARTAN/HCTZMYLAN-LOSARTAN HCTZPMS-LOSARTAN-HCTZSANDOZ LOSARTAN HCTSEPTA-LOSARTAN HCTZTEVA-LOSARTAN/HCTZHYZAAR
APO-LOSARTAN/HCTZAURO-LOSARTAN HCTLOSARTAN/HCTLOSARTAN/HCTZMINT-LOSARTAN/HCTZMYLAN-LOSARTAN HCTZPMS-LOSARTAN-HCTZSANDOZ LOSARTAN HCTTEVA-LOSARTAN/HCTZHYZAAR
APO-LOSARTAN/HCTZAURO-LOSARTAN HCTJAMP-LOSARTAN HCTZLOSARTAN/HCTLOSARTAN/HCTZMINT-LOSARTAN/HCTZ DSMYLAN-LOSARTAN HCTZPMS-LOSARTAN-HCTZSANDOZ LOSARTAN HCT DSSEPTA-LOSARTAN HCTZTEVA-LOSARTAN/HCTZHYZAAR DS
APXAURJPCSIVSNSMPIMYPPMSSDZSEPTEVMFC
APXAURSIVSNSMPIMYPPMSSDZTEVMFC
APXAURJPCSIVSNSMPIMYPPMSSDZSEPTEVMFC
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 1.3663
0.3082 0.3082 0.3082 0.3082 0.3082 0.3082 0.3082 0.3082 0.3082 1.3378
0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 0.3146 1.3663
71 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$$$$
$$$$$$$$$$
$$$$$$$$$$$$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
TELMISARTAN
TELMISARTAN/ AMLODIPINE BESYLATE
40 MG ORAL TABLET
80 MG ORAL TABLET
40 MG * 5 MG ORAL TABLET
40 MG * 10 MG ORAL TABLET
80 MG * 5 MG ORAL TABLET
80 MG * 10 MG ORAL TABLET
0000239324700002420082000024535680000237671700002375958000023889440000239034500002407485000023201770000243416400002240769
0000239325500002420090000024535760000237672500002375966000023889520000239035300002407493000023201850000243417200002240770
00002371022
00002371030
00002371049
00002371057
ACT TELMISARTANAPO-TELMISARTANAURO-TELMISARTANMYLAN-TELMISARTANSANDOZ TELMISARTANTELMISARTANTELMISARTANTELMISARTANTEVA-TELMISARTANVAN-TELMISARTANMICARDIS
ACT TELMISARTANAPO-TELMISARTANAURO-TELMISARTANMYLAN-TELMISARTANSANDOZ TELMISARTANTELMISARTANTELMISARTANTELMISARTANTEVA-TELMISARTANVAN-TELMISARTANMICARDIS
TWYNSTA
TWYNSTA
TWYNSTA
TWYNSTA
APHAPXAURMYPSDZSNSSIVAHITEVVANBOE
APHAPXAURMYPSDZSNSSIVAHITEVVANBOE
BOE
BOE
BOE
BOE
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 1.2182
0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 0.2161 1.2182
0.7125
0.7125
0.7125
0.7125
72 EFFECTIVE APRIL 1, 2018
$$$$$$$$$$$
$$$$$$$$$$$
$
$
$
$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
TELMISARTAN/ HYDROCHLOROTHIAZIDE
VALSARTAN
80 MG * 12.5 MG ORAL TABLET
80 MG * 25 MG ORAL TABLET
80 MG ORAL TABLET
160 MG ORAL TABLET
320 MG ORAL TABLET
000024191140000239326300002420023000024563890000239355700002390302000023953550000233028800002244344
0000241912200002420031000024563970000239356500002390310000023953630000237925200002318709
00002337495000023715290000241422800002383535000023631000000235675900002356651000023669590000238453100002244781
00002337509000023715370000241423600002383543000023631190000235676700002356678000023669670000238455800002244782
000023375170000237154500002414244000023835510000235677500002356686000023669750000238456600002289504
ACH-TELMISARTAN HCTZACT TELMISARTAN/HCTAPO-TELMISARTAN/HCTZAURO-TELMISARTAN HCTZSANDOZ TELMISARTAN HCTTELMISARTAN HCTZTELMISARTAN/HCTZTEVA-TELMISARTAN HCTZMICARDIS PLUS
ACH-TELMISARTAN HCTZAPO-TELMISARTAN/HCTZAURO-TELMISARTAN HCTZSANDOZ TELMISARTAN HCTTELMISARTAN HCTZTELMISARTAN/HCTZTEVA-TELMISARTAN HCTZMICARDIS PLUS
ACT VALSARTANAPO-VALSARTANAURO-VALSARTANMYLAN-VALSARTANRAN-VALSARTANSANDOZ VALSARTANTEVA-VALSARTANVALSARTANVALSARTANDIOVAN
ACT VALSARTANAPO-VALSARTANAURO-VALSARTANMYLAN-VALSARTANRAN-VALSARTANSANDOZ VALSARTANTEVA-VALSARTANVALSARTANVALSARTANDIOVAN
ACT VALSARTANAPO-VALSARTANAURO-VALSARTANMYLAN-VALSARTANSANDOZ VALSARTANTEVA-VALSARTANVALSARTANVALSARTANDIOVAN
AHIAPHAPXAURSDZSIVSNSTEVBOE
AHIAPXAURSDZSIVSNSTEVBOE
APHAPXAURMYPRANSDZTEVSNSSIVNOV
APHAPXAURMYPRANSDZTEVSNSSIVNOV
APHAPXAURMYPSDZTEVSNSSIVNOV
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.08
0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 1.2182
0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 1.2182
0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 1.2535
0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 0.2159 1.2528
0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 0.2098 1.2071
73 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$$$$$$$$$
$$$$$$$$
$$$$$$$$$$
$$$$$$$$$$
$$$$$$$$$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
PRODUCT IS NOT INTERCHANGEABLE
VALSARTAN/ HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE/ SPIRONOLACTONE
80 MG * 12.5 MG ORAL TABLET
160 MG * 12.5 MG ORAL TABLET
160 MG * 25 MG ORAL TABLET
320 MG * 12.5 MG ORAL TABLET
320 MG * 25 MG ORAL TABLET
25 MG * 25 MG ORAL TABLET
50 MG * 50 MG ORAL TABLET
00002382547000024081120000235669400002356996000023670090000238473600002241900
00002382555000024081200000235670800002357003000023670170000238474400002241901
00002382563000024081390000235671600002357011000023670250000238475200002246955
000023825710000240814700002356724000023570380000236703300002308908
000023825980000240815500002356732000023570460000236704100002308916
00000613231
00000657182
APO-VALSARTAN/HCTZAURO-VALSARTAN HCTSANDOZ VALSARTAN HCTTEVA-VALSARTAN/HCTZVALSARTAN HCTVALSARTAN HCTDIOVAN-HCT
APO-VALSARTAN/HCTZAURO-VALSARTAN HCTSANDOZ VALSARTAN HCTTEVA-VALSARTAN/HCTZVALSARTAN HCTVALSARTAN HCTDIOVAN-HCT
APO-VALSARTAN/HCTZAURO-VALSARTAN HCTSANDOZ VALSARTAN HCTTEVA-VALSARTAN/HCTZVALSARTAN HCTVALSARTAN HCTDIOVAN-HCT
APO-VALSARTAN/HCTZAURO-VALSARTAN HCTSANDOZ VALSARTAN HCTTEVA-VALSARTAN/HCTZVALSARTAN HCTDIOVAN-HCT
APO-VALSARTAN/HCTZAURO-VALSARTAN HCTSANDOZ VALSARTAN HCTTEVA-VALSARTAN/HCTZVALSARTAN HCTDIOVAN-HCT
TEVA-SPIRONOLACTONE/HCTZ
TEVA-SPIRONOLACTONE/HCTZ
APXAURSDZTEVSNSSIVNOV
APXAURSDZTEVSNSSIVNOV
APXAURSDZTEVSNSSIVNOV
APXAURSDZTEVSNSNOV
APXAURSDZTEVSNSNOV
TEV
TEV
CARDIOVASCULAR DRUGS
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24
24
:00
:00
24:32.08
24:32.20
0.2213 0.2213 0.2213 0.2213 0.2213 0.2213 1.2475
0.2240 0.2240 0.2240 0.2240 0.2240 0.2240 1.2507
0.2238 0.2238 0.2238 0.2238 0.2238 0.2238 1.2550
0.2235 0.2235 0.2235 0.2235 0.2235 1.2360
0.2231 0.2231 0.2231 0.2231 0.2231 1.2364
0.1307
0.2765
74 EFFECTIVE APRIL 1, 2018
$$$$$$$
$$$$$$$
$$$$$$$
$$$$$$
$$$$$$
$
$
(ANGIOTENSIN II RECEPTOR ANTAGONISTS)
(MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
ALBERTA DRUG BENEFIT LIST
SPIRONOLACTONE25 MG ORAL TABLET
100 MG ORAL TABLET00000613215
00000613223
TEVA-SPIRONOLACTONE
TEVA-SPIRONOLACTONE
TEV
TEV
CARDIOVASCULAR DRUGS
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS
24:00
24:32.20
0.1307
0.2989
75 EFFECTIVE APRIL 1, 2018UNIT OF ISSUE - REFER TO PRICE POLICY
$
$
(MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONISTS)
The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.